‘Standardized’ Comment From Brexit Minister Raises Hopes For Parallel EU/UK Drug Approval System

It was just one word but it is likely to have raised the hopes of those who insist a parallel drug approvals system between the UK and the EU will be needed if the UK does not become a member of the wider European Economic Area when it eventually leaves the EU.

David Davis, one of the senior government ministers responsible for negotiating the UK’s departure from the EU, was asked in the House of Commons whether he agreed with a warning from AstraZeneca CEO Pascal Soriot that “if we are not part of the European common approvals process the cost of drugs to the [National Health Service] will rise.” Davis’s